CNS Drugs
July 10, 2025
Eric A. Miller, Christy Capone, Erica Eaton et al.
4 citations
Psychedelics have been studied since the 1950s as a potential treatment for alcohol use disorder (AUD), with over a dozen clinical trials of lysergic acid diethylamide (LSD), and several contemporary trials of psilocybin and ayahuasca for this indication. Herein, we characterize foundational studies from the 1950s to the present, with emphasis on key design factors that varied considerably...
Psychiatry Research
May 1, 2024
Eric A. Miller, Houtan Totonchi Afshar, Jyoti Mishra et al.
12 citations
Ketamine helps some patients with treatment resistant depression (TRD), but reliable methods for predicting which patients will, or will not, respond to treatment are lacking. Herein, we aim to inform prediction models of non-response to ketamine/esketamine in adults with TRD. This is a retrospective analysis of PHQ-9 item response data from 120 patients with TRD who received repeated doses of...
medRxiv Preprint Server
July 3, 2023
Eric A. Miller, Houtan Totonchi Afshar, Jyoti Mishra et al.
preprint
Background Ketamine helps some patients with treatment resistant depression (TRD), but reliable methods for predicting which patients will, or will not, respond to treatment are lacking.
medRxiv Preprint Server
June 28, 2023
Mohammad Ali Shenasa, Houtan Totonchi Afshar, Eric A. Miller et al.
preprint
Background The antidepressant effects of ketamine and repetitive transcranial magnetic stimulation (rTMS) are hypothesized to rely on mechanisms of long-term-potentiation and synaptic plasticity. Cannabis, via activation of CB1 receptors has been shown to impair synaptic plasticity, suggesting that cannabis use might moderate the antidepressant effects of ketamine and/or rTMS.